Intuitive Surgical, Inc.
ISRGHealthcareNASDAQMedical Instruments & Supplies · Last scanned Oct 26, 2026
Scan Results
Daily timeframeIntuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company carries a $159.55B market cap, placing it firmly in the large-cap category. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung.
Market Cap
$159.55B
Beta
1.46
P/E (TTM)
54.61
P/E (Fwd)
36.33
EPS (TTM)
$8.27
EPS (Fwd)
$12.43
ROE
17.9%
ROA
11.8%
Cash
$4.04B
Total Debt
$0
Free CF
$3.43B
52W Change
-18.1%
Annual Financials
Cash vs Debt
Where ISRG stands vs its 150-day and 200-day moving averages
As of the October 9, 2026 close, ISRG finished 0.34% below its 150-day moving average ($416.81) and 6.48% below its 200-day moving average ($444.19). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ISRG overbought or oversold?
At the October 9, 2026 close, ISRG's RSI(14) was 64.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Intuitive Surgical, Inc. reports $4.04B in cash and $0 in total debt. Free cash flow comes in at $3.43B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 17.9%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 11.8% further supports the picture of efficient asset utilization. Revenue has grown from $6.22B (2022) to $10.06B (2025), reflecting a 62% increase over the period.
At over 50x earnings, ISRG carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ISRG.